Precision BioSciences (DTIL) AI Stock Analysis

• Market Cap: $99.42M
• Dividend Yield: N/A
• Average Volume (3M): 228.20K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.75
• Revenue Growth: -99.07%
• EPS Growth: -10347.56%
• Country: US
• Employees: 108
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -1.84
• Shares Outstanding: 24,071,750
• 10 Day Avg. Volume: 251,568
• 30 Day Avg. Volume: 228,198
• PEG Ratio: -0.03
• Price to Book (P/B): 0.46
• Price to Sales (P/S): 0.38
• P/FCF Ratio: -0.44
• Enterprise Value/Market Cap: 0.14
• Enterprise Value/Revenue: 19.48
• Enterprise Value/Gross Profit: -20.23
• Enterprise Value/Ebitda: -0.17
• 1Y Price Target: $45.00
• Price Target Upside: 1053.85% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2
• EPS Forecast (FY): -3.22
• Revenue Forecast (FY): $13.03M

• Rating: 46 Neutral
• Price Target: $4.00 ▲(2.56% Upside)

The score is held down primarily by weak financial performance (shrinking revenue, large losses, and negative cash flows) and bearish technical signals (below major moving averages with negative MACD). Positive clinical and strategic updates, including trial progress and a stated cash runway, provide some support but do not offset the current fundamental and trend weaknesses.

Positive Factors

Proprietary ARCUS platform & focused pipeline

Owning a differentiated gene‑editing platform (ARCUS) with two prioritized in‑vivo programs provides durable competitive advantage. A platform approach supports multiple indications, repeatable R&D outputs, and partnership/licensing opportunities that can compound value over time.

Positive ELIMINATE-B clinical signals

Robust early clinical readouts showing activity, safety and on‑target DNA editing materially reduce technical risk for PBGENE‑HBV. Durable antiviral effects and tolerability strengthen the program's path to later‑stage development and enhance partnerability and long‑term commercial prospects.

Material cash runway and partner payment

A reported ~$137M cash balance and recent partner proceeds provide a runway expected to fund key data milestones through 2028, lowering near‑term refinancing risk. This financial cushion enables continuation of development plans and preserves optionality for value‑creating catalysts.

Negative Factors

Steep revenue decline and large operating losses

Sharp revenue contraction and very wide negative margins reflect persistent unprofitability. Over months, this undermines internal funding capacity and increases reliance on external capital, making sustained investment in the pipeline contingent on non‑operating financing events.

Negative operating and free cash flow

Chronic negative operating cash flow indicates the business burns cash to fund operations and R&D. Continued cash burn forces repeat financings or partnerships, which can dilute shareholders and constrain strategic flexibility if clinical or commercial progress slows.

Reliance on equity raises and milestone funding

Listing an equity raise as a funding source highlights dependence on capital markets and milestone payments. This structural funding model exposes the company to dilution risk and timing risk: setbacks or missed milestones could force additional financing under unfavorable terms.

Precision BioSciences Business Overview & Revenue Model

Company Description

Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing and ex vivo allogeneic CAR T therapies in the United States. It offers ARCUS, a genome editing platform to cure genetic disorders. The company also provides Ex vivo Allogeneic CAR T Immunotherapy, a form of immunotherapy in which T cell, a specific type of immune cell is genetically engineered to recognize and kill cancer cells; PBCAR0191, which is in Phase 1/2a clinical trial in adult patients with R/R NHL or R/R B-cell precursor acute lymphoblastic leukemia, or B-ALL; PBCAR19B, an anti-CD19 CAR T candidate built on the stealth cell platform utilizing a single-step gene edit to minimize the risk of chromosome abnormalities; and PBCAR269A, an investigational allogeneic CAR T immunotherapy targeting BCMA for the treatment of R/R multiple myeloma. The company has development and commercial license agreement with Les Laboratoires Servier to develop allogeneic chimeric antigen receptor T cell therapies for antigen targets, hematological cancer targets beyond CD19, and solid tumor targets; Tiziana Life Sciences to evaluate foralumab, a fully human anti-CD3 monoclonal antibody as a lymphodepleting agent for the potential treatment of cancers; and iECURE, Inc. to develop ARCUS-based gene editing therapies. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.

How the Company Makes Money

Precision BioSciences generates revenue through a combination of product sales, research collaborations, and licensing agreements. The company partners with pharmaceutical and biotechnology firms to develop therapies using its ARCUS gene editing technology, earning revenue through milestone payments and royalties from successful product developments. Additionally, Precision BioSciences may receive funding from government grants and research contracts aimed at advancing its innovative therapies. Significant partnerships with other biotech companies enhance its revenue potential by allowing shared resources and expertise in drug development.

Precision BioSciences Financial Statement Overview

Summary

Precision BioSciences is facing significant financial difficulties, characterized by declining revenues, substantial losses, and negative cash flows. While there are some improvements in leverage, the company's profitability and cash generation remain major concerns.

Income Statement

Precision BioSciences has faced significant challenges in its income statement, with a negative revenue growth rate of -44.65% in the TTM period, indicating a sharp decline in sales. The company also reported negative margins across the board, with a net profit margin of -119.77% and an EBIT margin of -87.0%, highlighting substantial losses relative to revenue. These factors suggest a struggling financial performance with limited profitability.

Balance Sheet

The balance sheet shows a mixed picture. The debt-to-equity ratio improved to 0.09 in the TTM period, indicating lower leverage compared to previous years. However, the return on equity remains deeply negative at -213.79%, reflecting ongoing losses. The equity ratio stands at 17.79%, suggesting a moderate level of equity financing relative to total assets.

Cash Flow

Cash flow analysis reveals a challenging situation with negative operating cash flow and free cash flow. The free cash flow growth rate improved by 14.43% in the TTM period, but the operating cash flow to net income ratio of -4.89 indicates that cash outflows significantly exceed net income. The free cash flow to net income ratio of 1.00 suggests that free cash flow is closely aligned with net income, albeit both are negative.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	698.00K	68.70M	48.73M	25.10M	115.53M	24.29M
Gross Profit	-672.00K	68.70M	48.73M	25.10M	115.53M	24.29M
EBITDA	-79.30M	13.53M	-32.04M	-62.79M	-20.27M	-99.19M
Net Income	-83.60M	7.17M	-61.32M	-111.64M	-30.60M	-109.01M
Balance Sheet
Total Assets	93.51M	136.39M	159.78M	238.17M	211.50M	150.16M
Cash, Cash Equivalents and Short-Term Investments	44.87M	86.31M	116.68M	189.58M	143.66M	89.80M
Total Debt	29.13M	30.05M	31.27M	24.96M	9.11M	10.52M
Total Liabilities	76.88M	80.00M	140.92M	177.74M	120.33M	105.73M
Stockholders Equity	16.63M	56.39M	18.86M	60.43M	91.17M	44.42M
Cash Flow
Free Cash Flow	-73.69M	-58.70M	-86.39M	-49.07M	-16.66M	-92.42M
Operating Cash Flow	-73.28M	-58.45M	-84.11M	-45.75M	-10.85M	-87.39M
Investing Cash Flow	-406.00K	-215.00K	5.83M	-3.32M	-5.80M	-5.03M
Financing Cash Flow	23.57M	50.45M	5.39M	94.98M	70.52M	1.33M

Precision BioSciences Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 3.90
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DTIL, the sentiment is Negative. The current price of 3.9 is below the 20-day moving average (MA) of 4.28, below the 50-day MA of 4.97, and below the 200-day MA of 5.09, indicating a bearish trend. The MACD of -0.26 indicates Negative momentum. The RSI at 39.99 is Neutral, neither overbought nor oversold. The STOCH value of 40.84 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for DTIL.

Precision BioSciences Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CTMX	63 Neutral	$728.57M	10.16	66.76%	―	-10.26%	144.62%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
ACRV	49 Neutral	$57.75M	-0.88	-50.23%	―	―	21.17%
DTIL	46 Neutral	$99.42M	-0.46	-205.16%	―	-99.07%	-10347.56%
ACET	46 Neutral	$79.41M	-0.39	-71.73%	―	―	25.89%
IMA	45 Neutral	$80.00M	-0.81	-33.05%	―	-100.00%	45.48%

Precision BioSciences Corporate Events

Precision BioSciences Highlights 2026 Gene Editing Priorities

On January 12, 2026, Precision BioSciences outlined its 2026 strategic priorities centered on advancing its two lead ARCUS-based in vivo gene editing programs—PBGENE-HBV for chronic hepatitis B and PBGENE-DMD for Duchenne muscular dystrophy—while emphasizing a solid cash position of approximately $137 million as of December 31, 2025, which it expects will support key data milestones through 2028. The company reported encouraging safety and antiviral activity data from multiple dosing cohorts in its global Phase 1/2a ELIMINATE-B trial for PBGENE-HBV, with plans to complete dosing in Cohorts 3, 4, and 5, select an optimal regimen to enable stopping nucleos(t)ide analog treatment, and move into trial expansion, while also preparing to initiate patient dosing in the Phase 1/2 FUNCTION-DMD trial in early 2026 and deliver initial Duchenne data by year-end; additional value drivers include partnered programs ECUR-506 and azer-cel, which have reached significant regulatory and clinical milestones and triggered an $8 million payment in late 2025, underscoring Precision’s strengthened financial and strategic position in the gene editing field.

The most recent analyst rating on (DTIL) stock is a Hold with a $3.50 price target. To see the full list of analyst forecasts on Precision BioSciences stock, see the DTIL Stock Forecast page.

Precision BioSciences Announces $70M Stock Offering

On November 10, 2025, Precision BioSciences, Inc. announced an underwriting agreement with Guggenheim Securities, LLC for the sale of 10,815,000 shares of common stock and accompanying warrants, expecting to raise approximately $70 million. The proceeds will be used for research and development, working capital, and other corporate purposes, with the offering’s closing anticipated on November 12, 2025, subject to customary conditions.

The most recent analyst rating on (DTIL) stock is a Buy with a $60.00 price target. To see the full list of analyst forecasts on Precision BioSciences stock, see the DTIL Stock Forecast page.

Precision BioSciences Unveils Promising ELIMINATE-B Trial Results

On November 10, 2025, Precision BioSciences announced significant findings from its ELIMINATE-B clinical trial, which evaluates the PBGENE-HBV therapy for hepatitis B. The trial demonstrated consistent antiviral activity and durable reductions in hepatitis B surface antigen across various dose levels, with no dose-limiting toxicities observed. The promising results, including direct evidence of HBV DNA editing, suggest a potential path to a cure, positioning the company favorably in the gene editing landscape and offering hope for stakeholders seeking effective hepatitis B treatments.

The most recent analyst rating on (DTIL) stock is a Hold with a $6.00 price target. To see the full list of analyst forecasts on Precision BioSciences stock, see the DTIL Stock Forecast page.